comparemela.com
Home
Live Updates
Nivolumab With Ipilimumab Have an Added Benefit in Mesothelioma : comparemela.com
Nivolumab With Ipilimumab Have an Added Benefit in Mesothelioma
A pure antibody combination is approved as first-line therapy for unresectable malignant pleural mesothelioma for the first time. Added benefit is not yet proven for patients with epithelioid histology.
Related Keywords
Germany ,
German ,
,
Efficiency In Health Care Iqwi ,
German Institute For Quality ,
German Institute ,
Health Care ,
Mesothelioma ,
Nivolumab Ipilimumab ,
Drug Combination ,
Malignancy ,
Leural Tumors ,
Pithelioid Tumors ,
comparemela.com © 2020. All Rights Reserved.